Genetic Immunity, LLC – Product Pipeline Review – 2012

  • June 2012
  • -
  • Global Markets Direct
  • -
  • 31 pages

Genetic Immunity, LLC – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “Genetic Immunity, LLC - Product Pipeline Review - 2012” provides data on the Genetic Immunity, LLC’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Genetic Immunity, LLC’s corporate website, SEC filings, investor presentations and featured press releases, both from Genetic Immunity, LLC and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Genetic Immunity, LLC - Brief Genetic Immunity, LLC overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Genetic Immunity, LLC human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Genetic Immunity, LLC with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Genetic Immunity, LLC’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Genetic Immunity, LLC’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Genetic Immunity, LLC in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Genetic Immunity, LLC’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Genetic Immunity, LLC.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Genetic Immunity, LLC and identify potential opportunities in those areas.

Table Of Contents

Genetic Immunity, LLC - Product Pipeline Review - 2012
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Genetic Immunity, LLC Snapshot 5
Genetic Immunity, LLC Overview 5
Key Information 5
Key Facts 5
Genetic Immunity, LLC - Research and Development Overview 6
Key Therapeutic Areas 6
Genetic Immunity, LLC - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Genetic Immunity, LLC - Pipeline Products Glance 10
Genetic Immunity, LLC Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
Genetic Immunity, LLC - Early Stage Pipeline Products 11
Pre-Clinical Products/Combination Treatment Modalities 11
Discovery Products/Combination Treatment Modalities 12
Genetic Immunity, LLC - Drug Profiles 13
ChlamyDerm Vaccine 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
DermAll Vaccine 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
DermaVir 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
HupaDerm Vaccine 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
ProstaDerm Vaccine 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
Genetic Immunity, LLC - Pipeline Analysis 18
Genetic Immunity, LLC - Pipeline Products by Therapeutic Class 18
Genetic Immunity, LLC - Pipeline Products By Target 19
Genetic Immunity, LLC - Pipeline Products by Route of Administration 20
Genetic Immunity, LLC - Recent Pipeline Updates 21
Genetic Immunity, LLC - Locations And Subsidiaries 22
Head Office 22
Other Locations and Subsidiaries 22
Genetic Immunity, LLC, Recent Developments 23
Genetic Immunity, LLC- Press Release 23
May 17, 2012: Genetic Immunity Publishes Data From DermaVir Clinical Trial in PLoS ONE 23
Jun 11, 2009: Company completes patient enrollment in Phase II trial of DermaVir Patch HIV immunotherapeutic nanomedicine lead product candidate 23
Apr 16, 2009: Second Phase II clinical trial commences in Italy on Company's lead product candidate DermaVir Patch HIV vaccine 24
Financial Deals Landscape 26
Genetic Immunity, LLC, Deals Summary 26
Genetic Immunity, LLC, Pharmaceuticals and Healthcare, Deal Details 27
Venture Financing 27
Genetic Immunity Secures $2 Million In Bridge Financing 27
Partnerships 28
Power Of The Dream Ventures Enters Into Co-development Agreement With Genetic Immunity 28
Licensing Agreements 29
Genetic Immunity Enters Into Licensing Agreement With Aldevron 29
Appendix 30
Methodology 30
Coverage 30
Secondary Research 30
Primary Research 30
Expert Panel Validation 30
Contact Us 31
Disclaimer 31

List of Tables

Genetic Immunity, LLC, Key Information 5
Genetic Immunity, LLC, Key Facts 5
Genetic Immunity, LLC - Pipeline by Indication, 2012 7
Genetic Immunity, LLC - Pipeline by Stage of Development, 2012 8
Genetic Immunity, LLC - Monotherapy Products in Pipeline, 2012 9
Genetic Immunity, LLC - Phase II, 2012 10
Genetic Immunity, LLC - Pre-Clinical, 2012 11
Genetic Immunity, LLC - Discovery, 2012 12
Genetic Immunity, LLC - Pipeline By Therapeutic Class, 2012 18
Genetic Immunity, LLC - Pipeline By Target, 2012 19
Genetic Immunity, LLC - Pipeline By Route of Administration, 2012 20
Genetic Immunity, LLC - Recent Pipeline Updates, 2012 21
Genetic Immunity, LLC, Other Locations 22
Genetic Immunity, LLC, Deals Summary 26
Genetic Immunity Secures $2 Million In Bridge Financing 27
Power Of The Dream Ventures Enters Into Co-development Agreement With Genetic Immunity 28
Genetic Immunity Enters Into Licensing Agreement With Aldevron 29

List of Figures

Genetic Immunity, LLC - Pipeline by Indication, 2012 7
Genetic Immunity, LLC - Pipeline by Stage of Development, 2012 8
Genetic Immunity, LLC - Monotherapy Products in Pipeline, 2012 9
Genetic Immunity, LLC - Pipeline By Therapeutic Class, 2012 18
Genetic Immunity, LLC - Pipeline By Target, 2012 19

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Genetic Analysis AS - Medical Equipment - Deals and Alliances Profile

Genetic Analysis AS - Medical Equipment - Deals and Alliances Profile

  • $ 250
  • Company report
  • January 2015
  • by Global Data

Summary Genetic Analysis AS (Genetic Analysis) is a molecular diagnostic company. The company focuses in the molecular diagnostics of diseases related to gut imbalances. It has developed DNA-based GA-map ...

Genetic Technologies Limited

Genetic Technologies Limited

  • $ 55
  • Company report
  • March 2015
  • by Wright Investors' Service

A textual analysis of the financial results for Genetic Technologies Limited compared to selected competitors. Also included are quantitative analyses of the company's financial statements, extensive ...

Rosetta Genomics, Ltd. (ROSG) - Medical Equipment - Deals and Alliances Profile

Rosetta Genomics, Ltd. (ROSG) - Medical Equipment - Deals and Alliances Profile

  • $ 250
  • Company report
  • January 2015
  • by Global Data

Summary Rosetta Genomics, Ltd. (RGL) is a biotechnology company. The company discovers, develops and commercializes next generation diagnostic tests for personalized medicine. It provides testing services ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.